Heart failure and cardiac hypertrophy

被引:18
|
作者
Rame J.E. [1 ]
Dries D.L. [1 ]
机构
[1] Division of Cardiology, University of California San Francsiso, San Francisco, CA 94143-0124
关键词
Heart Failure; Left Ventricular Hypertrophy; Losartan; Carvedilol; Main Drug Interaction;
D O I
10.1007/s11936-007-0024-3
中图分类号
学科分类号
摘要
Left ventricular failure is the final common pathway for a wide spectrum of myocardial insults, including systemic hypertension and myocardial infarction. Although left ventricular hypertrophy is an adaptive response to pressure and volume overload, this process becomes maladaptive if left untreated and pathologic cardiac hypertrophy then becomes an important and independent risk factor for the development of heart failure. Despite its importance, the transition from hypertrophy to heart failure in humans is poorly understood. The focus of treatment should be prevention of heart failure and other cardiovascular events, such as stroke and atrial fibrillation. When heart failure is present, treatment with medical and device therapy is then focused on improving functional capacity, increasing survival, and preventing progression to end-stage heart failure. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:289 / 301
页数:12
相关论文
共 50 条
  • [31] Angiogenic Endothelial Cell Signaling in Cardiac Hypertrophy and Heart Failure
    Gogiraju, Rajinikanth
    Bochenek, Magdalena L.
    Schaefer, Katrin
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2019, 6
  • [32] Roles of histone acetylation sites in cardiac hypertrophy and heart failure
    Funamoto, Masafumi
    Imanishi, Masaki
    Tsuchiya, Koichiro
    Ikeda, Yasumasa
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [33] Angiogenesis and Cardiac Hypertrophy Maintenance of Cardiac Function and Causative Roles in Heart Failure
    Oka, Toru
    Akazawa, Hiroshi
    Naito, Atsuhiko T.
    Komuro, Issei
    CIRCULATION RESEARCH, 2014, 114 (03) : 565 - 571
  • [34] Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure
    Ohtani, Tomohito
    Mano, Toshiaki
    Hikoso, Shungo
    Sakata, Yasushi
    Nishio, Mayu
    Takeda, Yasuharu
    Otsu, Kinya
    Miwa, Takeshi
    Masuyama, Tohru
    Hori, Masatsugu
    Yamamoto, Kazuhiro
    JOURNAL OF HYPERTENSION, 2009, 27 (05) : 1074 - 1083
  • [35] Summary of the Cologne Conference on Heart Failure: transition from cardiac hypertrophy to failure
    Petra Schnabel
    M. Böhm
    Journal of Molecular Medicine, 1998, 76 : 721 - 722
  • [36] Summary of the Cologne Conference on Heart Failure:: transition from cardiac hypertrophy to failure
    Schnabel, P
    Böhm, M
    JOURNAL OF MOLECULAR MEDICINE-JMM, 1998, 76 (11): : 721 - 722
  • [37] Inhalation of diesel exhaust does not exacerbate cardiac hypertrophy or heart failure in two mouse models of cardiac hypertrophy
    Liu, Yonggang
    Chien, Wei-Ming
    Medvedev, Ivan O.
    Weldy, Chad S.
    Luchtel, Daniel L.
    Rosenfeld, Michael E.
    Chin, Michael T.
    PARTICLE AND FIBRE TOXICOLOGY, 2013, 10
  • [38] Inhalation of diesel exhaust does not exacerbate cardiac hypertrophy or heart failure in two mouse models of cardiac hypertrophy
    Yonggang Liu
    Wei-Ming Chien
    Ivan O Medvedev
    Chad S Weldy
    Daniel L Luchtel
    Michael E Rosenfeld
    Michael T Chin
    Particle and Fibre Toxicology, 10
  • [39] Cardiac-specific ablation of glutaredoxin 3 leads to cardiac hypertrophy and heart failure
    Donelson, Jimmonique
    Wang, Qiongling
    Monroe, Tanner O.
    Jiang, Xiqian
    Zhou, Jianjie
    Yu, Han
    Mo, Qianxing
    Sun, Qin
    Marini, Juan C.
    Wang, Xinquan
    Nakata, Paul A.
    Hirschi, Kendal D.
    Wang, Jin
    Rodney, George G.
    Wehrens, Xander Ht
    Cheng, Ninghui
    PHYSIOLOGICAL REPORTS, 2019, 7 (08):
  • [40] CARDIAC-FAILURE .5. THE PROGRESSION FROM HYPERTROPHY TO HEART-FAILURE
    TARAZI, RC
    HOSPITAL PRACTICE, 1983, 18 (08) : 101 - +